FAS and leukemia: The molecular profiles of AML exosomes isolated from pre-therapy plasma were enriched in leukemia associated antigens (LAAs) and in proteins that mediate immune suppression, such as TGF-β1/LAP, CD39/CD73 ectoenzymes, PD1/PD-L1 or Fas/FasL (Fig. 2a).